Four cases of central nervous system involvement by granulocytic sarcoma (three intracranial and one paraspinal) in children with acute nonlymphocytic leukemia (FAB M1 or M2 subtype) are presented, and therapeutic modalities are discussed. All tumors were noted at initial presentation with diagnosis being made on clinical and radiological findings without biopsy. All patients had karyotypic abnormalities: three had translocation of chromosomes 8 and 21, and one had an unspecified hypodiploid clone. The three patients who developed intracranial tumors responded well to triple agent (cytosine arabinoside, hydrocortisone, and methotrexate) intrathecal chemotherapy and systemic chemotherapy, with or without local irradiation, as evidenced by rapid disappearance of the tumors. Two children are disease-free after 17 and 57 months. One patient with paraspinal tumor failed to achieve a systemic remission but had no evidence of granulocytic sarcoma at autopsy. Thus, the prognosis of CNS granulocytic sarcoma is not uniformly gloomy if treated aggressively by combined modalities. The value of surgical intervention in terms of primary management, however, is limited.
Introduction
Granulocytic sarcoma (chloroma) is an extramedullary accumulation of predominantly primitive cells of the myeloid series that tends to occur in younger patients with acute nonlymphocytic leukemia (ANLL) [1 -3] . This tumor type can develop at any body site but most commonly occurs in the tissues of the orbital region, bone, soft tissue, skin, and sinuses. Involvement of the central nervous system (CNS) by granulocytic sarcoma has been considered to be unusual. However, the frequency is expected to increase because of therapeutic advances in systemic therapy. The optimal management of this tumor remains to be established; experience has thus far been limited because of small patient numbers. We present four cases of CNS granulocytic sarcoma that were present at diagnosis in childhood ANLL. Other case reports are reviewed to better elucidate the biological and clinical significance of this complication of leukemia.
Materials and methods
The medical records of all patients, aged 15 years or younger, who were treated for ANLL in the Department of Pediatrics, The University of Texas M.D. Anderson Hospital and Tumor Institute at Houston between 1970 and 1985, were reviewed to document intracranial or paraspinal granulocytic sarcoma (chloroma), defined as CNS granulocytic sarcoma. The diagnosis of ANLL was based on morphological, cytogenetic, and cytochemical examinations that included periodic acid-Schiff (PAS), myeloperoxidase, naphthol AS-D chloroacetate esterase, and nonspecific esterase staining of initial bone marrow smears. Clot sections of bone marrow aspirates were studied with light and electron microscopy. The FrenchAmerican-British (FAB) classification system of ANLL [4] was performed on all patients registered after 1977. Specimens were submitted for cytogenetic studies on the majority of the patients registered after 1975. Chromosome analyses were performed on bone marrow aspirates obtained at the time of diagnosis. The techniques employed have been previously reported [5] . The bone marrow cells were cultured overnight in Ham's F10 medium supplemented with 20% fetal bovine serum. No mitotic stimulants were used. G-banding procedures were utilized on the chromosome preparations following a trypsin pretreatment. A maximum of twenty-five metaphases were analyzed and the results were reported according to the International System of Human Cytogenetic Nomenclature.
The diagnosis of granulocytic sarcoma was based on clinical findings and radiologic examinations, including computed tomography (CT) scanning and myelography. Lumbar puncture was routinely performed at presentation of the disease and thereafter at regular intervals. Cerebrospinal fluid was evaluated for malignant cells by cytocentrifugation followed by Wright-Giemsa staining.
Results
A review of the records of 108 children admitted to M.D. Anderson Hospital between 1970 and 1985 with acute nonlymphocytic leukemia showed that 17 of the children (15.7%) developed granulocytic sarcoma (chloroma) in the orbital area, soft tissue, lymph node, mediastinum, brain, paraspinal region, skin, or bone. Karyotypic abnormalities were observed in 9 of the 10 patients evaluated; 6 had a translocation involving chromosomes 8 and 21.
Four of 108 children that were treated for ANLL had CNS granulocytic sarcoma (three intracranial and one paraspinal). All tumors were present at diagnosis. All patients had cytogenetic abnormalities in bone marrow karyotypes: three had translocation of chromosomes 8 and 21 and one had an unspecified hypodiploid clone. All 8;21 translocations were also associated with missing sex chromosomes. Three patients were classified as having FAB M2 subtype ANLL and one had M1 subtype.
Three children received combined therapy including local irradiation, intrathecal chemotherapy, and systemic induction chemotherapy. Intrathecal chemotherapy consisted of methotrexate (MTX, 12 mg/m2), hydrocortisone (HDC, 15 rag/m2), and cytosine arabinoside (Ara-C, 30mg/m2). One child received intrathecal chemotherapy and systemic induction chemotherapy without irradiation. No surgical intervention, either for diagnosis or decompression, was performed.
Two of four patients are disease-free after 17 and 57 months. One child with a lower paraspinal tumor died without having achieved a marrow remission, but autopsy revealed complete resolution of the tumor; the other child died six months after the diagnosis. In two patients with intracranial granulocytic sarcoma, the tumor had regressed completely following primary intrathecal chemotherapy and systemic induction therapy and before cranial radiation therapy. In one case, regression of the tumor was observed by CT scan within two weeks of initiation of systemic therapy and one course of IT medication. The presenting features of these four patients are summarized in Table 1 , and illustrative case reports are presented.
Case reports
Case One A 14-year-old boy developed cellulitis of the leg. Laboratory examination disclosed the following: Within 24 hours of admission, the patient developed signs of lower spinal cord compression with bilateral paresis of the lower legs. Admission neurological examination had been normal. He then developed acute neurogenic bladder and loss of bowel function. An emergency myelogram revealed complete spinal block at the inferior level of T6. Radiation therapy was begun with 3 000 tad to the spine from T1 to Tg, followed by craniospinal irradiation using 2400 tad and systemic chemotherapy, including Ara-C and 6-thioguanine. The patient regained some spontaneous movement of the lower extremities but was unable to stand or walk unassisted. Although his general status improved with these therapies, no systemic remission could be induced. He died ll weeks after diagnosis. Results of autopsy demonstrated subdural and subarachnoid hemorrhage of the brain and spinal cord; however, no evidence of local, residual leukemic infiltration was found.
Case Three
A four-year-old boy who was in good health until April 1982, when he developed a left otitis media, which was treated by oral antibiotics. One week later he began complaining of headache and was noted to have drooping of the left side of the face. A maxillary tumor was found. A biopsy was interpreted as malignant lymphoma and he was referred to M.D. Anderson Hospital. Physical examination revealed marked swelling of the left side of the face associated with left facial nerve palsy. Bilateral papilledema was also noted. The liver and spleen were not palpable. Laboratory evaluation revealed the following; WBC count, 5300/ml with 39°70 blasts; hemoglobin, 8.7 g/dl; and platelet count, 239000/ml. Bone marrow was infiltrated with blast cells strongly positive for peroxidase and esterase stains. Numerous Auer bodies were also noted. Periodic acid-Schiff and nonspecific esterase stains were negative. A cytogenetic study revealed the presence of (45,X,-Y,t[8q-;21q + ]). A diagnosis of ANLL (FAB M1 subtype) was made. Pathological review of the maxillary tumor was consistent with granulocytic sarcoma. A skull X ray revealed marked spitting of the cranial sutures, presumably secondary to increased intracranial pressure. Complete opacification of the left maxillary sinus was also noted. ACT scan of the head disclosed a mass in the left maxillary sinus extending into the left nasal cavity with destruction of the medial wall. Furthermore, lobulated intracranial masses were also noted in the left temporal, frontal, and parietal regions, all of which markedly enhanced with con-trast medium (Fig. 1) . Although no histopathological documentation of intracranial tumor was available, a myeloblastic origin was assumed in view of the clinical course. The patient was started on systemic chemotherapy, including vincristine, Ara-C, and dexamethasone, and radiation therapy using 3000 rad to the skull and maxilla. Prompt response to these measures was evidenced by complete disappearance of the tumors in the maxillary sinus and brain (Fig. 2) . The finding of increased intracranial pressure precluded a lumbar puncture at the initial work-up; it was performed four weeks later for the first time, and the results were normal. After a hematologic remission was obtained, the patient was treated on cyclic maintenance chemotherapy for 18 months. He remains in initial complete remission 57 months after the diagnosis. A follow-up CT scan is shown in Fig. 3 . This child has learning disabilities. He is currently in special education classes and required two years to complete kindergarten. 
Case Four
An eleven year old girl developed headaches, chest pain and progressive pallor. A complete blood count showed hemoglobin 3.2 gm%0, white blood count 4800/ml with 36% blasts, and platelets 28 000/ml. Symptoms resolved with a transfusion of packed red cells. A bone marrow aspirate showed FABM2 Auer rod positive blasts which were perioxidase, PAS, choroacetate esterase and Tdt positive. A cytogenetic analysis showed the presence of 45, X, -X, t[Sq;21q+] blasts. She was begun on systemic induction with daunorubicin, Ara C and 6TG; a single intrathecal injection of methotrexate, Ara C and hydrocortisone was administered. Cerebrospinal fluid cytology was negative. A routine CT scan showed a modular contrast enhanced tumor adjacent to the lateral ventricle. A follow up CT scan done 3 weeks later showed marked resolution of the mass. Her induction regimen was repeated; intrathecal chemotherapy was also administered. A follow up CT scan showed complete resolution. More intensive intrathecal chemotherapy along with cranial irradiation was then given. Follow up CT scan done 6 months from diagnosis showed no evidence for recurrence. She remains in CNS and marrow remission. She has not received further therapy directed at the CNS.
Discussion
Granulocytic sarcomas usually develop in patients with a known diagnosis of nonlymphocytic leukemia, although development of tumors may precede the diagnosis of leukemia [6] [7] [8] [9] [10] . Routine morphological methods are limited for making a definitive pathologic diagnosis of these tumors. Naphthol AS-D chloroacetate esterase staining seems to be the most conclusive yet simplest method for differential diagnosis [10] , especially when applied on freshly prepared slides [11] , and should be included in the diagnostic workup. Although reported survival rates of patients who developed granulocytic sarcoma appear to be similar to survival rates of patients without those 375 tumors [6, 9] , the ultimate prognosis has been invariably poor in pediatric patients [2, 3, 8] . The tumor develops at various stages of nonlymphocytic leukemia with a reported frequency ranging from 2.9 to 6.8% [2, 9, 12] . Major progress in the treatment of ANLL has occured during the past decade; more than 25% of children with ANLL have been in initial complete remission for two years with intensive therapy [13] [14] [15] [16] . Thus, the actual frequency of granulocytic sarcoma is probably higher than reports suggest. We have observed development of granulocytic sarcoma in 17 of 108 children (15.7%) with ANLL in a 16-year period of time (Unpublished data).
The reported frequency of CNS involvement in ANLL ranges from 25 to 38% [17] [18] , but most cases involve diffuse meningeal infiltration. The actual occurrence of CNS granulocytic sarcoma is unusual. None of 323 patients with ANLL reported by Muss and Moloney [12] developed intracranial tumors, although two of them developed paraspinal tumors. Liu et al. [2] reported that five of 338 patients with myelogenous leukemia developed intracranial tumors. Neiman et al. [10] reported that among 61 biopsy-proven granulocytic sarcomas, seven developed in the vertebral and paravertebral regions, and only one tumor developed in the brain. A recent report by Pui et al. [19] from St. Jude Children's Research Hospital documented that two of 184 children with ANLL developed intracerebral mass. They also reported the development of paraspinal granulocytic sarcoma in one of 309 children with ANLL at presentation [20] and two of 297 children throughout their course of ANLL [21] . In 1981, Petursson and Boggs [22] reviewed 67 previously published cases of spinal cord involvement in leukemia patients and found that 31 had acute myeloid leukemia. Clinical features and therapeutic modalities in welldocumented recent reports of CNS granulocytic sarcoma are summarized in Table 2 [2, 6, 7, 20, [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] . Most of the previously published cases of CNS granulocytic sarcoma developed in older patients; the clinical and biological significance of this complication of leukemia in pediatric patients is obscure. In our series, CNS involvement by granulocytic sarcoma was found at diagnosis in Previous reports on patients with intracranial granulocytic sarcoma have indicated that the progress of the disease in the adult population is relatively slow, as shown in Table 2 . All intracranial tumors that developed in three patients reported by Pippard et al. [30] were highly sensitive to radiation therapy; two of the patients survived 34 + and 22 + months after the tumor developed. The patients reported by Hurwitz et al. [7] and Ballard et al. [24] survived 18 months and 31 months after the development of intracranial granulocytic sarcoma. In our study, two of three patients with intracranial tumor survived: one has been followed 57 months after the initital diagnosis of leukemia (41 months after discontinuation of all therapy).
Most reports have indicated that patients with intracranial tumors benefit from radiation therapy, with or without intrathecal chemotherapy [6, 7, 30] . Chemosensitivity of granulocytic sarcoma has not been completely evaluated, although it was suggested in some reports [6, 35] . In our study, two patients were treated with intrathecal therapy and systemic chemotherapy without radiation therapy. Notably, Case 4 received only a single course of triple intrathecal therapy in addition to systematic chemotherapy including continuous infusion of Ara-C. Ara-C is known to be effective for prevention and treatment of CNS leukemia. Intrathecal chemotherapy, employing three drugs or Ara-C alone, may have tumoricidal ability, although intrathecal methotrexate alone seems to be ineffective [25] . Considering the high chemosensitivity of the tumors observed in our patients, whole skull irradidation could concievably be excluded from the primary treatment, particularly in younger patients, to avoid adverse effects of the therapy on the immature brain.
Computed tomography scanning plays a major role in the diagnosis of CNS granulocytic sarcoma because of the tumor's relatively consistent appearance. On CT scanning, it is usually seen as a mass with increased attenuation with surrounding 379 edema, which is uniformly enhanced following injection of contrast material [28, 29, 34] . Based on these findings and the clinical information, a preliminary diagnosis can be made and confirmed when there is a dramatic response to therapy. Routine surveillance of the CNS system by CT scanning should be included in the initial diagnostic workup in children with ANLL. Laboratory evaluation of CSF has only limited value in the diagnosis of intracranial granulocytic sarcoma.
Extensive reviews of paraspinal granulocytic sarcoma have been published [22, 35] . The tumor may be the presenting symptom of leukemia and may be confused with primary orthopedic disease. Upon development of paraspinal granulocytic sarcoma, it is important to establish an early diagnosis and administer proper therapy to prevent permanent neurological damage from spinal cord compression by the tumor [36] . Even then, as shown by our Case 1, rapid recognition and treatment may not be successful. Myelography is the primary diagnostic procedure for defining disease extension. However, a lumbar puncture procedure may aggravate the neurological dysfunction and be disadvantageous to the patient. Considering the high chemo-and radiosensitivity of this type of tumor [22] , paraspinal granulocytic sarcoma should be primarily treated by high-dose corticosteroids followed by systemic chemotherapy and radiation therapy.
There has been no comprehensive study of the karyotypic abnormalities in patients with CNS granulocytic sarcoma. In our study, all four children who developed CNS granulocytic sarcoma also had abnormalities in the karyotype; three had translocation of chromosomes 8 and 21, and one had an unspecified hypodiploid clone. Leukemia associated with 8;21 transloeation is known to have a good prognosis [37, 38] but also is closely related to the development of granulocytic sarcoma [39] [40] [41] . The relatively benign course of ANLL observed in patients with CNS granulocytic sarcoma may often be explained by the frequent association of this particular karyotypic change.
